BIS News and Press, ProShares UltraShort Nasdaq Biotechnology From 08/01/22

After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpo...

Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. An investment analysis follows in the paragraphs below. Don't live the same year 75 tim...

Incyte is outperforming the SP 500. Institutions are accumulating shares. My price target on INCY is $100. Incyte Corp. is Moving Higher Incyte Corporation ( INCY ) is a biopharmaceutical company that is outperforming the SP 500 index. There are several bullish i...

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...

Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phas...

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such ...

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...

Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...